Pharming cuts 2026 revenue outlook to US$375-US$395 million

Reuters2026/07/30 05:21

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pharming cut full-year 2026 revenue guidance to US$375-395 million, lowered by US$30 million.
Operating expense forecast tightened to US$315-320 million, improved by US$15 million.
Outlook assumes significant Joenja growth, RUCONEST revenue stabilization, return to growth in the second half.
Q2 revenue totaled US$90.2 million, down 3% year-on-year; Joenja rose 40% to US$17.9 million; RUCONEST fell 10% to US$72.3 million.
Cash and marketable securities stood at US$159.5 million at quarter-end, down US$12.3 million from Q1 due to working-capital movements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pharming cuts 2026 revenue outlook to US$375-US$395 million

You may also like

Crypto prices